During the past decade, NYU Winthrop Hospital, Gynecologic Oncology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "NYU Winthrop Hospital, Gynecologic Oncology" are "Ovarian Cancer" (2 trials). Many other conditions were trialed in "NYU Winthrop Hospital, Gynecologic Oncology" in a lesser frequency.

Most popular intervention types in "NYU Winthrop Hospital, Gynecologic Oncology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (1 trials), "Chemotherapy + avelumab followed by avelumab + talazoparib" (1 trials), "Chemotherapy + bevacizumab followed by bevacizumab" (1 trials), "Chemotherapy followed by talazoparib maintenance" (1 trials) and "carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "NYU Winthrop Hospital, Gynecologic Oncology" are 2 trials for "Female" genders.

Currently, there are NaN active trials in "NYU Winthrop Hospital, Gynecologic Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in NYU Winthrop Hospital, Gynecologic Oncology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in NYU Winthrop Hospital, Gynecologic Oncology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".